nach oben

Digestive Diseases and Sciences

Erschienen in:

01.03.2009 | Case Report

Clinical Benefits and Cost-Effectiveness of 17-Year Treatment with Low-Dose Interferon-α 2b in a Patient with Chronic Hepatitis C: A Case Report

verfasst von: Takumi Kawaguchi, Shuji Sumie, Minoru Itou, Eitaro Taniguchi, Tsunetaka Matoba, Michio Sata

Erschienen in: Digestive Diseases and Sciences | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Excerpt

Interferon-α (IFN-α) is now used to treat chronic hepatitis C worldwide [1, 2]. Pharmaceutical properties of IFN-α have antiviral, anti-inflammatory, and anti-tumor activities [3]. Thus, IFN-α can be used at various stages of hepatitis C virus (HCV)-related liver diseases including liver cirrhosis and hepatocellular carcinoma (HCC) [4‐9]. …

Iino S, Hino K, Yasuda K (1994) Current state of interferon therapy for chronic hepatitis C. Intervirology 37:87–100PubMed

Hoofnagle JH, di Bisceglie AM (1997) The treatment of chronic viral hepatitis. N Engl J Med 336:347–356. doi:10.1056/NEJM199701303360507 PubMedCrossRef

Tilg H (1997) New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 112:1017–1021. doi:10.1053/gast.1997.v112.pm9041265 PubMedCrossRef

Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S et al (1995) Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346:1051–1055. doi:10.1016/S0140-6736(95)91739-X PubMedCrossRef

Schalm SW, Fattovich G, Brouwer JT (1997) Therapy of hepatitis C: patients with cirrhosis. Hepatology 26:128S–132S. doi:10.1002/hep.510260722 PubMedCrossRef

Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M et al (1999) Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT study group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 131:174–181PubMed

Omata M, Yoshida H, Shiratori Y (2005) Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy. Clin Gastroenterol Hepatol 3:S141–S143. doi:10.1016/S1542-3565(05)00713-5 PubMedCrossRef

Hasegawa E, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T et al (2007) Efficacy and anticarcinogenic activity of interferon for hepatitis C virus-related compensated cirrhosis in patients with genotype 1b low viral load or genotype 2. Hepatol Res 37:793–800. doi:10.1111/j.1872-034X.2007.00140.x PubMedCrossRef

Kudo M, Sakaguchi Y, Chung H, Hatanaka K, Hagiwara S, Ishikawa E et al (2007) Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case–control study. Oncology 72(Suppl 1):132–138. doi:10.1159/000111719 PubMedCrossRef

10.

Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T et al (2006) Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130:1086–1097. doi:10.1053/j.gastro.2006.02.015 PubMedCrossRef

11.

Guerret S, Desmouliere A, Chossegros P, Costa AM, Badid C, Trepo C et al (1999) Long-term administration of interferon-alpha in non-responder patients with chronic hepatitis C: follow-up of liver fibrosis over 5 years. J Viral Hepat 6:125–133. doi:10.1046/j.1365-2893.1999.00148.x PubMedCrossRef

12.

Murashima S, Tanaka M, Haramaki M, Yutani S, Nakashima Y, Harada K et al (2006) A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP. Dig Dis Sci 51:808–812. doi:10.1007/s10620-006-3211-2 PubMedCrossRef

13.

Nomura H, Kashiwagi Y, Hirano R, Tanimoto H, Tsutsumi N, Higashi M et al (2007) Efficacy of low dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetoprotein: a pilot study. Hepatol Res 37:490–497. doi:10.1111/j.1872-034X.2007.00073.x PubMedCrossRef

14.

Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S et al (2006) Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 44:1543–1554. doi:10.1002/hep.21415 PubMedCrossRef

15.

Hayashida K, Nagasue I, Fukuda T, Gunji A (2002) The natural history model of hepatitis C virus infection and the economic evaluation of alpha interferon treatment. J Epidemiol 12:22–32PubMed

16.

Shiratori Y, Kato N, Yoshida H, Nakata R, Ihori M, Imazeki F et al (2000) Sustained viral response is rarely achieved in patients with high viral load of HCV RNA by excessive interferon therapy. Dig Dis Sci 45:565–574. doi:10.1023/A:1005457510354 PubMedCrossRef

17.

Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N (2007) Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 11:1–205 iiiPubMed

18.

Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C et al (1998) Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International hepatitis interventional therapy group. N Engl J Med 339:1493–1499. doi:10.1056/NEJM199811193392102 PubMedCrossRef

19.

Dusheiko G (1997) Side effects of alpha interferon in chronic hepatitis C. Hepatology 26:112S–121S. doi:10.1002/hep.510260720 PubMedCrossRef

20.

Itoh H, Nakata H, Yokoya Y, Nakashima S, Yamanishi T, Hara T et al (1996) Efficacy and side effects of intermittent recombinant interferon-alpha 2a in chronic aggressive hepatitis C: with or without initial daily administration. J Gastroenterol Hepatol 11:718–723. doi:10.1111/j.1440-1746.1996.tb00320.x PubMedCrossRef

21.

Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A et al (2001) Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 357:196–197. doi:10.1016/S0140-6736(00)03595-9 PubMedCrossRef

22.

Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N et al (2007) Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C. J Med Virol 79:1095–1102. doi:10.1002/jmv.20866 PubMedCrossRef

23.

Arase Y, Ikeda K, Tsubota A, Suzuki F, Suzuki Y, Saitoh S et al (2004) Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection. Intervirology 47:355–361. doi:10.1159/000080880 PubMedCrossRef

24.

Gomez-Rubio M, Porres JC, Castillo I, Quiroga JA, Moreno A, Carreno V (1990) Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group. J Hepatol 11(Suppl 1):S63–S67. doi:10.1016/0168-8278(90)90166-O PubMedCrossRef

25.

Yousuf M, Nakano Y, Tanaka E, Sodeyama T, Kiyosawa K (1992) Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up. Scand J Gastroenterol 27:812–826. doi:10.3109/00365529209011189 PubMedCrossRef

26.

Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL (1997) Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 127:855–865PubMed

27.

Buti M, Casado MA, Fosbrook L, Wong JB, Esteban R (2000) Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C. J Hepatol 33:651–658. doi:10.1034/j.1600-0641.2000.033004651.x PubMedCrossRef

28.

Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R (2003) A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther 17:687–694. doi:10.1046/j.1365-2036.2003.01453.x PubMedCrossRef

29.

Gildea TR, Shermock KM, Singer ME, Stoller JK (2003) Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 167:1387–1392. doi:10.1164/rccm.200209-1035OC PubMedCrossRef

30.

Ishida H, Inoue Y, Wong JB, Okita K (2004) Cost-effectiveness of ribavirin plus interferon alpha-2b for either interferon relapsers or non-responders in chronic hepatitis C: a Japanese trial. Hepatol Res 28:125–136. doi:10.1016/j.hepres.2003.11.002 PubMedCrossRef

31.

San Miguel R, Mar J, Cabases JM, Guillen-Grima F, Buti M (2003) Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon. Aliment Pharmacol Ther 17:765–773. doi:10.1046/j.1365-2036.2003.01494.x PubMedCrossRef

32.

Younossi ZM, Singer ME, McHutchison JG, Shermock KM (1999) Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 30:1318–1324. doi:10.1002/hep.510300518 PubMedCrossRef

Titel: Clinical Benefits and Cost-Effectiveness of 17-Year Treatment with Low-Dose Interferon-α 2b in a Patient with Chronic Hepatitis C: A Case Report
verfasst von: Takumi Kawaguchi
Shuji Sumie
Minoru Itou
Eitaro Taniguchi
Tsunetaka Matoba
Michio Sata
Publikationsdatum: 01.03.2009
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 3/2009
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-008-0397-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Clinical Benefits and Cost-Effectiveness of 17-Year Treatment with Low-Dose Interferon-α 2b in a Patient with Chronic Hepatitis C: A Case Report

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2009

Assessment of Pre-Gastroscopy Fasting Period Using Ultrasonography

The Effects of Capsaicin on Gastrin Secretion in Isolated Human Antral Glands: Before and After Ingestion of Red Chilli

Prevalence of Barrett’s Esophagus in Patients with or without GERD Symptoms: Role of Race, Age, and Gender

Central Nervous System Plus Autonomic Nervous System Disorders Responsible for Gastrointestinal and Pancreatobiliary Diseases

Post-sphincterotomy Transampullary Balloon Dilation Is a Safe and Effective Technique

Are 12 Nodes Needed to Accurately Stage T1 and T2 Colon Cancers?

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin